Category - News

Markets

HCW cuts ReWalk Robotics PT to $3.50 from $9

H.C. Wainwright lowered its price target for ReWalk Robotics (NASDAQ:RWLK) to $3.50 from $9, reflecting dilution from a recent public offering. The stock closed at 81 cents on Feb. 20. As a result of the financing, the...

February 21, 2020

Developments

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VBL Therapeutics (NASDAQ:VBLT) launched a Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer. VB-111, an adenovirus that carries a transgene for the Fas...

February 20, 2020

Developments

VistaGen reports positive results from Phase 2a major depressive disorder study

VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...

February 20, 2020

Developments

Mesoblast moving remestemcel-L into chronic GVHD pivotal trial

Mesoblast (NASDAQ:MESO; ASX:MSB) achieved clinically meaningful outcomes in all three treated patients, two children and one adult, within 28 days after two infusions of its allogeneic cell therapy product candidate...

February 20, 2020

Executive Moves

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

Jean Gauvin Kane Biotech (TSX-V:KNE) appointed renowned Canadian veterinarian, Dr. Jean Gauvin, as its chief veterinary officer. Dr. Gauvin will serve as a liaison between Kane Biotech and industry; guide the company’s...

February 20, 2020

Markets

BTIG halves Endologix PT to $6 from $12

BTIG halved its price target for Endologix (NASDAQ:ELGX) to $6 from $12, but maintained its “buy” rating, saying the new target better reflects the current stock price, which closed at 89 cents on Feb. 19. Endologix...

February 20, 2020

Developments

Obalon opens second retail treatment center to treat obesity

Obalon Therapeutics (NASDAQ:OBLN) opened its second company-managed retail center in Orange County, Calif. to treat obesity with its swallowable, gas-filled intragastric balloon system. In a statement, Bill Plovanic...

February 20, 2020

Markets

WB cuts Tivity Health to market perform

William Blair downgraded Tivity Health (NASDAQ:TVTY) to “market perform” after fourth quarter results missed consensus estimates and Tivity announced the departure of several senior executives. The stock closed at $22...

February 20, 2020

Developments

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells. The...

February 19, 2020

Developments

Five Prime misses primary endpoint in pancreatic cancer trial

Five Prime Therapeutics (NASDAQ:FPRX) reported that its Phase 2 trial evaluating cabiralizumab in combination with Opdivo, with and without chemotherapy, in patients with advanced pancreatic cancer failed to meet its...

February 18, 2020

Category - News

HCW cuts ReWalk Robotics PT to $3.50 from $9

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VistaGen reports positive results from Phase 2a major depressive disorder study

Mesoblast moving remestemcel-L into chronic GVHD pivotal trial

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

BTIG halves Endologix PT to $6 from $12

Obalon opens second retail treatment center to treat obesity

WB cuts Tivity Health to market perform

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Five Prime misses primary endpoint in pancreatic cancer trial

General

More